Funding Round
<cite index="1-2">Chai Discovery, the company engineering artificial intelligence (AI) models to discover new molecules, announced a $400 million Series C fundraise on July 14, 2026.</cite> <cite index="1-3">The round, which values the company at $3.8 billion, was led by Index Ventures alongside Kleiner Perkins, Sequoia Capital, and Dimension.</cite> <cite index="3-4,3-5">New investors Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, and Avra Capital joined the round, as did existing backers Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures, General Catalyst, Glade Brook, Avenir, Lachy Groom, and Yosemite.</cite>
<cite index="4-15">Chai Discovery has raised approximately $630 million across four rounds since its founding in 2024.</cite> <cite index="13-9,13-10">A seed round of approximately $30 million, backed by Thrive Capital, OpenAI, and Dimension, was followed by a $70 million Series A in August 2025 led by Menlo Ventures. A $130 million Series B co-led by Oak HC/FT and General Catalyst followed in December 2025, bringing the company to unicorn status at a $1.3 billion valuation.</cite> <cite index="5-6">The Series C valuation is nearly triple the $1.3 billion the company was worth seven months ago.</cite>
Company Background and Technology
<cite index="15-7">Chai Discovery was founded in 2024 by Joshua Meier, Jack Dent, Matthew McPartlon, and Jacques Boitreaud.</cite> <cite index="11-16">The founding team brings backgrounds spanning OpenAI, Meta FAIR, Stripe, molecular design, and academic research.</cite>
<cite index="11-6">Chai Discovery builds AI models to accelerate pre-clinical drug discovery, predicting and reprogramming the interactions between molecules.</cite> <cite index="8-9">Rather than screening existing chemical libraries, the founders built a platform premised on the idea that AI could generate entirely new therapeutic molecules from first principles.</cite> <cite index="13-16">The platform's foundation model, Chai-1, performs multimodal biomolecular structure prediction across proteins, small molecules, DNA, and RNA simultaneously, including their interactions.</cite>
<cite index="13-17">Chai-2, released in 2025, added a generative layer: a full-atom diffusion architecture capable of designing complete antibody sequences and structures from scratch, conditioned only on a target protein and a specified binding epitope.</cite> <cite index="13-18">The company reported that Chai-2 achieved experimental hit rates of approximately 16–20% in fully de novo antibody design, compared to rates below 1% for prior computational methods.</cite> <cite index="4-10">Chai-3, the current generation, is reported to reduce the antibody design failure rate by approximately 50% relative to Chai-2 and to improve binding affinity and multi-specific molecule engineering.</cite>
Commercial Partnerships
<cite index="13-13">In January 2026, Chai announced a research collaboration with Eli Lilly and Co. that included development of a bespoke AI model trained on Lilly's proprietary data.</cite> <cite index="13-14">A license agreement with Pfizer, announced in June 2026, granted Pfizer early access to Chai-3 alongside a custom model tailored to Pfizer's workflows.</cite> <cite index="13-15">The day before the Series C was announced, Chai disclosed a collaboration with Novartis to advance AI-driven antibody discovery, extending its roster of major pharma partners to three.</cite> <cite index="14-27">Chai also added a collaboration with immunology firm argenx in the same week.</cite>
Investor Commentary and Use of Proceeds
Sequoia Capital partner Pat Grady cited real-world traction as the central basis for participation. <cite index="11-10,11-11">"Drug discovery is one of the hardest problems in science. For a long time, there's been a dream that AI will solve it," Grady said. "Chai's product velocity and real-world partnerships with Eli Lilly, Pfizer, and more of the biggest names in pharma are starting to turn this dream into a reality."</cite> <cite index="13-5">The company said proceeds will be used to further accelerate AI model development and expand platform capabilities, though specific allocation details were not disclosed.</cite>
Broader Market Context
<cite index="14-30">Analysts put the AI drug-discovery market at approximately $2.35 billion in 2025, projected to grow to $13.7 billion by 2033.</cite> Chai is not alone in attracting large institutional commitments to this segment. <cite index="5-36">Isomorphic Labs, Google DeepMind's drug-discovery spinout, closed a $2.1 billion round in May 2026 and also counts Novartis as a partner.</cite> <cite index="8-15">Xaira Therapeutics launched with $1 billion in funding, and Recursion Pharmaceuticals has raised more than $1 billion across public and private markets.</cite>
<cite index="18-15,18-16">Drug discovery remains one of science's highest-risk industries, where promising molecules must still survive years of laboratory validation, clinical trials, and regulatory scrutiny before reaching patients—a timeline that does not compress simply because a model can generate candidates faster.</cite>